Health Services
(asked on 18th January 2017) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what policy proposals the Clinical Priority Advisory Group assigned priority level (a) 1, (b) 2, (c) 3, (d) 4 and (e) 5 to the specialised commissioning re-prioritisation process for 2016-17, announced on 4 December 2016.
Information on the annual prioritisation process for specialised treatments was announced by NHS England on 4 December 2016. This can be found here:
https://www.england.nhs.uk/2016/12/hiv-prevention-pregramme/
The final outcomes of the 2016-17 prioritisation were as follows:
Recommended for routine commissioning | Not recommended for routine commissioning |
- Pegvisomant for acromegaly as a third-line treatment for adults | - Eculizumab for treatment of recurrence of C3 glomerulopathy post-transplant |
- Auditory brainstem implants for congenital abnormalities of the auditory nerves or cochleae | - Riociguat for pulmonary arterial hypertension |
- Haematopoietic stem cell transplant for Lymphoplasmacytic lymphoma /Waldenstrom’s Macroglobulinaemia (adults) | - Second allogeneic haematopoietic stem cell transplant for relapsed disease |
- Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex |
|
- Rituximab for immunoglobulin-G4 related disease (IgG4-RD) |
|
- Microprocessor controlled prosthetic knees |
|
- Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) for patients who require cancer chemotherapy |
|
- Ivacaftor for children (2-5 years) with cystic fibrosis (named mutations) |
|
- Sodium oxybate for symptom control for narcolepsy with cataplexy (children) |
|
- Pasireotide for Cushing’s Disease |
|